Literature DB >> 8122703

Hearing preservation following a transtemporal resection of an acoustic schwannoma: a case report.

P G Smith1, D C Bigelow, G R Kletzker, J P Leonetti, B K Pugh, E T Mishler.   

Abstract

The transtemporal or translabyrinthine approach is generally regarded as the most reliable method of ensuring total tumor removal and preservation of facial nerve function in the resection of a cerebellopontine angle tumor. This is particularly true in removing a tumor that has a significant extension into the patient's internal auditory canal. An anticipated deficit associated with the approach is a total hearing loss in the patient's hearing on the operated side. We have encountered a patient, however, who was serially documented as having serviceable hearing after a transtemporal removal of an acoustic schwannoma. Plausible reasons for the functional preservation of some of this patient's hearing are included in the discussion.

Entities:  

Mesh:

Year:  1993        PMID: 8122703     DOI: 10.1097/00129492-199309000-00003

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  4 in total

1.  Cochlear Patency after Translabyrinthine and Retrosigmoid Vestibular Schwannoma Surgery.

Authors:  Huibert Frans van Waegeningh; Elke Loos; Tony Van Havenbergh; Thomas Somers
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

2.  Hearing Improvement after Partial Labyrinthectomy: Resection of petrous apex cholesterol granuloma.

Authors:  Abdulrahman A Hagr
Journal:  Sultan Qaboos Univ Med J       Date:  2010-07-19

3.  Hearing preservation after translabyrinthine approach performed to remove a large vestibular schwannoma.

Authors:  Stéphane Tringali; Chantal Ferber-Viart; Stéphane Gallégo; Christian Dubreuil
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-03-08       Impact factor: 2.503

4.  Partial Hearing Preservation after Translabyrinthine Vestibular Schwannoma Resection: Case Report and Review of the Literature.

Authors:  Syed F Ahsan; Dennis Bojrab; Robert Standring
Journal:  J Neurol Surg Rep       Date:  2015-08-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.